Markman M, DeMarco L C, Birkhofer M, Budman D, Hakes T, Reichman B, Rubin S, Jones W, Barakat R, Curtin J
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
J Cancer Res Clin Oncol. 1993;119(4):234-6. doi: 10.1007/BF01624436.
There is a critical need to find new chemotherapeutic agents that are active in platinum-refractory ovarian cancer. A phase II trial of zeniplatin (CL 286,558), a third-generation platinum compound, was conducted in 31 patients with advanced ovarian cancer to examine the safety and activity of the agent when used as a salvage treatment in individuals previously exposed to organoplatinum-based therapy. In general the drug was well tolerated, with moderate emesis and bone marrow suppression being observed in most patients. An unexpected side-effect was significant fever, of unknown etiology, which was noted in 16% of patients. Out of 20 patients, 2 (10%; 95% confidence intervals: 1%-32%) with clinically defined platinum-refractory disease achieved a partial response. Unfortunately, although we have defined definite but modest activity for zeniplatin in platinum-refractory ovarian cancer, further development of this drug has been discontinued because of the severe renal toxicity observed in other clinical trials of this cytotoxic agent.
迫切需要找到对铂耐药卵巢癌有效的新型化疗药物。对31例晚期卵巢癌患者进行了第三代铂化合物泽尼铂（CL 286,558）的II期试验，以研究该药物在先前接受过有机铂类治疗的个体中作为挽救治疗时的安全性和活性。总体而言，该药物耐受性良好，大多数患者出现中度呕吐和骨髓抑制。一个意外的副作用是原因不明的显著发热，16%的患者出现此症状。在20例临床定义为铂耐药疾病的患者中，2例（10%；95%置信区间：1%-32%）获得部分缓解。不幸的是，尽管我们已确定泽尼铂在铂耐药卵巢癌中有一定但适度的活性，但由于在该细胞毒性药物的其他临床试验中观察到严重肾毒性，该药物已停止进一步研发。
